Entry inhibitors work outside the cell. They prevent HIV from entering the CD4 cell by blocking binding or fusion of HIV with the CD4 cell membrane. If HIV cannot enter the CD4 cell it is unable to replicate.

Fusion and Entry inhibitors

Non-nucleoside reverse transcriptase

inhibitors

Non-nucleoside reverse transcriptase inhibitors bind to reverse transcriptase and inhibit the enzyme, stopping HIV replication by preventing formation of HIV DNA. These drugs act in a completely different way to nucleoside / nucleotide analogues.

Nucleoside/Nucleotide analogues

Nucleoside / nucleotide analogues act as false substrates for reverse transcriptase, causing chain termination. The resulting DNA is incomplete and prevents HIV replication.

Integrase inhibitors

Integrase inhibitors block the integration of HIV and cell DNA. This process prevents HIV replication.

Protease inhibitors

Protease inhibitors work at the last stage of the HIV replication cycle. They prevent HIV from being successfully assembled and released from the infected CD4 cell.

TARGETING HIV REPLICATION1,2

Stages of HIV replication

1. HIV enters a CD4 cell.

2. HIV is a retrovirus, meaning that its genetic information is stored on single-stranded RNA instead of the double-stranded DNA found in most organisms.

3. HIV DNA enters the nucleus of the CD4 cell and inserts itself into the cell’s DNA. HIV DNA then instructs the cell to make many copies of the original virus.

4. New virus particles are assembled and leave the cell, ready to infect other CD4 cells.

Antiretroviral Agents for HIV

Antiretroviral AgentsAdult Dosage CardAUGUST 2018

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING. Product information is available from the relevant manufacturer.

Viramune®, Aptivus® are registered trademarks of Boehringer Ingelheim Pty Ltd. Stocrin®, Isentress® are registered trademarks of Merck Sharp & Dohme.

Intelence®, Edurant®, Prezista®, Prezcobix® are registered trademarks of Janssen-Cilag Pty Ltd.

Reyataz®, Evotaz™ are registered trademarks of Bristol-Myers Squibb Australia Pty Ltd.

Retrovir, 3TC, Combivir, Ziagen, Kivexa, Trizivir, Telzir, Celsentri, Tivicay, Triumeq, Juluca Trade marks are owned by or licensed to the ViiV Healthcare group of companies.

Viread®, Truvada®, Descovy®, Atripla®, Eviplera®, Odefsey®, Stribild®, Genvoya®, Biktarvy® are registered trademarks of Gilead Sciences Pty Ltd.

Kaletra®, Norvir® are registered trademarks of AbbVie Pty Ltd. Fuzeon®, Invirase® are registered trademarks of F Hoffmann-La Roche AG.

For information on ViiV Healthcare products or to report an adverse event involving a ViiV Healthcare product,

please contact GSK Medical Information on 1800 499 226 or e-mail Australia.medinfo@viivhealthcare.com

ViiV Healthcare Pty Ltd. Level 3, 436 Johnston St, Abbotsford VIC 3067, ACN 138 687 448.

© 2018 ViiV Healthcare group of companies or its licensor. Date of preparation: August 2018. AUS/HIV/0117/18

Reference: 1. Adapted from Murphy K et al. Janeway’s Immunobiology, 8th Edition Garland Science, 2012 Chapter 13.

2. Adapted from Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.

Downloaded from https://aidsinfo.nih.gov/guidelines

The Antiretroviral Agents Adult Dosage Card was originally developed by Boehringer Ingelheim and we acknowledge their contribution to HIV management.

PROT

EASE

INHI

BITO

RS (P

I)

SINGL

E PILL

REGIM

ENS

Juluca(dolutegravir/rilpivirine)

1 x 50 mg / 25 mg tablet once daily

Triumeq(dolutegravir/abacavir/lamivudine)

1 x 50 mg / 600 mg / 300 mg tablet once daily

Biktarvy®(tenofovir alafenamide/emtricitabine/bictegravir)

1 x 25 mg / 200 mg / 50 mg tablet once daily

Odefsey®(tenofovir alafenamide/emtricitabine/rilpivirine)

1 x 25 mg / 200 mg / 25 mg tablet once daily

Genvoya®(tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat)

1 x 10 mg / 200 mg / 150 mg / 150 mg tablet once daily

Stribild®(tenofovir disoproxil fumarate/ emtricitabine/elvitegravir/cobicistat)

1 x 300 mg / 200 mg / 150 mg / 150 mg tablet once daily

Eviplera®(tenofovir disoproxil fumarate/emtricitabine/rilpivirine)

1 x 300 mg / 200 mg / 25 mg tablet once daily

Atripla®(tenofovir disoproxil fumarate/ emtricitabine/efavirenz)

1 x 300 mg / 200 mg / 600 mg tablet once daily

® Registered Trademark TM Trademark † Please refer to product information before prescribing as dosing may change with some combinations or patient types *Or as directed by physician

NON

-NUC

LEOS

IDE

REVE

RSE

TRAN

SCRI

PTAS

E IN

HIBI

TORS

(NN

RTI)

Viramune®

(nevirapine)1 x 200 mg tablet 2 times a day 1 x 400 mg tablet once daily

or

Stocrin®(efavirenz)

1 x 600 mg tablet once daily

Intelence®(etravirine)

1 x 200 mg tablet 2 times a day

Edurant®(rilpivirine)

1 x 25 mg tablet once daily

100 mg / 25 mg also available (not shown)

INTE

GRAS

E INH

IBITO

RS

Isentress®(raltegravir)

1 x 400 mg tablet 2 times a day 2 x 600 mg tablets once dailyor

Tivicay(dolutegravir)

1 x 50 mg tablet once daily

CLASS/DRUG USUAL ADULT DAILY DOSING† *

(products depicted in this column are not the actual size) ACTUAL SIZE CLASS/DRUG USUAL ADULT DAILY DOSING† *

(products depicted in this column are not the actual size) ACTUAL SIZE CLASS/DRUG USUAL ADULT DAILY DOSING† *

(products depicted in this column are not the actual size) ACTUAL SIZEN

UCL

EOSI

DE

/ NU

CLEO

TID

E RE

VERS

E TR

AN

SCRI

PTA

SE IN

HIB

ITO

RS (N

RTI /

NtR

TI)

ENTR

Y IN

HIBI

TORS

Fuzeon®(enfuvirtide) also known as T-20

1 x 90 mg vial 2 times a day

Celsentri(maraviroc)

1 x 150 mg tab or 1 x 300 mg tab or 2 x 300 mg tabs2 times a day 2 times a day 2 times a day

Fuzeon is available as powder for reconstitution (90 mg vial) for

subcutaneous injection

Crixivan®(indinavir)

2 x 400 mg capsules 3 times a day

Invirase®(saquinavir)

2 x 500 mg tablets 2 times a day

Kaletra®(lopinavir/ritonavir)

2 x 200 mg / 50 mg tablets 2 times a day 4 x 200 mg / 50 mg tablets once dailyor

Telzir(fosamprenavir calcium)

1 x 700 mg tablet 2 times a day 2 x 700 mg tablets once dailyor

Reyataz®(atazanavir)

1 x 300 mg capsule once daily 2 x 200 mg capsules once dailyor

Evotaz™(atazanavir/cobicistat)

1 x 300 mg / 150 mg tablet once daily

Aptivus®(tipranavir)

2 x 250 mg capsules 2 times a day

Prezista®(darunavir)

1 x 800 mg tablet once daily 1 x 600 mg tablet 2 times a dayor

Prezcobix®(darunavir/cobicistat)

1 x 800 mg / 150 mg tablet once daily

Norvir®(ritonavir)

6 x 100 mg tablets 2 times a day

Retrovir(zidovudine) also known as AZT

2 x 100 mg capsules 3 times a day 1 x 250 mg capsule 2 times a dayor

3TC(lamivudine)

1 x 150 mg tablet 2 times a day 1 x 300 mg tablet once dailyor

Combivir(lamivudine/zidovudine)

1 x 150 mg / 300 mg tablet 2 times a day

Ziagen(abacavir)

1 x 300 mg tablet 2 times a day 2 x 300 mg tablets once dailyor

Kivexa(abacavir/lamivudine)

1 x 600 mg / 300 mg tablet once daily

Trizivir(abacavir/lamivudine/zidovudine)

1 x 300 mg / 150 mg / 300 mg tablet 2 times a day

Emtriva®(emtricitabine) also known as FTC

1 x 200 mg capsule once daily

Viread®(tenofovir disoproxil fumarate)

1 x 300 mg tablet once daily

Truvada®(tenofovir disoproxil fumarate/emtricitabine)

1 x 300 mg / 200 mg tablet once daily

Descovy®(tenofovir alafenamide/emtricitabine)

1 x 25 mg / 200 mg tablet once daily 1 x 10 mg / 200 mg tablet once dailyor Antiretroviral Agents

Adult Dosage CardAUGUST 2018